Contact this trialFirst, we need to learn more about you.
Alkylating agents
BEAM vs. Melphalan for Multiple Myeloma
Recruiting1 awardPhase 2
Seattle, Washington
This trial aims to compare the effectiveness of two different treatments for multiple myeloma. The first treatment is the standard of care, which is Melphalan. The second treatment is BEAM, which has not been well studied in multiple myeloma specifically, but has been studied in other lymphomas. Early data suggests that BEAM may be effective in multiple myeloma, but there is not enough data to know for sure. This trial will help to determine whether BEAM is more effective than Melphalan.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.